Trial Profile
A Randomized, Controlled, Open-Label Study Investigating the Safety and Efficacy of Degarelix Given Intermittently vs Continuous Androgen Deprivation Therapy With Lupron or Degarelix in Patients With Prostate Cancer With Prior Treatment Failure After Localized Treatment
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Degarelix (Primary) ; Leuprorelin
- Indications Prostate cancer
- Focus Registrational; Therapeutic Use
- Sponsors Ferring Pharmaceuticals
- 09 Oct 2020 Results of post hoc analysis of data pooled from two post-hoc analysis from two phase 3b trials (NCT00295750-Global and NCT00928434 USA assessing the survival endpoints, published in the Journal of Urology
- 16 May 2017 Pooled results of trials (NCT00295750 and NCT00928434) presented at the 112th Annual Meeting of the American Urological Association
- 01 Sep 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.